ESC Guidelines in 2023 for the Management of Cardiomyopathy and Strategies for Prevention and Treatment of Sudden Cardiac Death in Cardiomyopathy
Wu Lin
Zhang An
Abstract：Cardiomyopathy is a complex condition characterized with structural and functional abnormalities of the myocardium.The etiology is multifaceted,and primary cardiomyopathy is related to those with unknown causes,esp.genetic mutations.The cate-gory encompasses hypertrophic,dilated,non-dilated left ventricular myocardial diseases,restrictive and arrhythmogenic right ventric-ular cardiomyopathy,as well as unclassified myocardial diseases.Mutations of genes encoding myocardial cells are important in the pathogenesis of cardiomyopathy.The prognosis of cardiomyopathy relies on the etiology,severity,treatment strategies,and the overall health status of patients.In August 2023,the"2023 ESC Guidelines for the management of myocardial diseases"were published.The guidline includes all types of cardiomyopathy and offers diagnostic and therapeutic guidance for various cardiomyopathy,emphasi-zing non-dilated left ventricular and pediatric cardiomyopathy.Diagnosis and treatment of cardiomyopathy based on this guideline,as well as sudden cardiac death associated with cardiomyopathy are reviewed.
Keywords：cardiomyopathysudden cardiac deathgene mutationmanagementprognosis
Publication Date：2024-04-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：8( 1-8 )